Key result
Dedicated CHIP clinic evaluation sees lipid-lowering therapy initiated or escalated in ~72% of patients.
Why the study?
Despite observational data linking CHIP to adverse cardiovascular outcomes, the cardiovascular evaluation and management of individuals with clonal hematopoiesis remain undefined.
Observational (n=53)
No
A dedicated CHIP Cardiology Clinic is feasible and frequently leads to the initiation or escalation of preventive cardiovascular medications, particularly lipid-lowering therapies, in patients with clonal hematopoiesis.
Authors
No takes yet. Share an insight, caveat, or question.
May support dedicated CHIP clinics for lipid-lowering optimization; hypothesis-generating for CV outcomes.
Oren et al. (2026) conducted an observational in Clonal hematopoiesis (CH) and clonal hematopoiesis of indeterminate potential (CHIP) (n=53). CHIP Cardiology Clinic evaluation was evaluated on Initiation or escalation of lipid-lowering therapies. Evaluation in a dedicated CHIP Cardiology Clinic led to the initiation or escalation of lipid-lowering therapies in 71.8% of patients with clonal hematopoiesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: